2016). Using the fluorescent properties of STO-609 as a tool to assist structure-function analyses of recombinant CaMKK2. Using the fluorescent properties of STO-609 as a tool to assist structure-function analyses of recombinant CaMKK2, and j.p.morth@ncmm.uio.no Abbreviations AMPK, adenosine monophosphate-regulated kinase; CaM, calmodulin; CaMK, calcium/calmodulin-dependent kinase; CaMKK2, calcium/calmodulin-dependent kinase kinase 2; CaMKK2:CaM, CaMKK2-CaM complex Abstract Calcium/calmodulin-dependent kinase kinase 2 (CaMKK2) has been implicated in the regulation of metabolic activity in cancer and immune cells, and affects whole-body metabolism by regulating ghrelin-signalling in the hypothalamus. This has led to efforts to develop specific CaMKK2 inhibitors, and STO-609 is the standardly used CaMKK2 inhibitor to date. We have developed a novel fluorescence-based assay by exploiting the intrinsic fluorescence properties of STO-609. Here, we report an in vitro binding constant of K D ~17 nM between STO-609 and purified CaMKK2 or CaMKK2:Calmodulin complex. Whereas high concentrations of ATP were able to displace STO-609 from the kinase, GTP was unable to achieve this confirming the specificity of this association. Recent structural studies on the kinase domain of CaMKK2 had implicated a number of amino acids involved in the binding of STO-609. Our fluorescent assay enabled us to confirm that Phe 267 is critically important for this association since mutation of this residue to a glycine abolished the binding of STO-609. An ATP replacement assay, as well as the mutation of the 'gatekeeper' amino acid Phe 267 Gly, confirmed the specificity of the assay and once more confirmed the strong binding of STO-609 to the kinase. In further characterising the purified kinase and kinasecalmodulin complex we identified a number of phosphorylation sites some of which corroborated previously reported CaMKK2 phosphorylation and some of which, particularly in the activation segment, were novel phosphorylation events.
In conclusion, the intrinsic fluorescent properties of STO-609 provide a great opportunity to utilise this drug to label the ATP-binding pocket and probe the impact of mutations and other regulatory modifications and interactions on the pocket. It is however clear that the number of phosphorylation sites on CaMKK2 will pose a challenge in studying the impact of Introduction Calcium/calmodulin-dependent kinase kinase 1 and 2 (CaMKK1 and CaMKK2) has been identified as kinases capable of phosphorylating calcium/calmodulin-dependent kinases 1 and 4 (CaMK1 and CaMK4) and the adenosine monophosphate-regulated kinase (AMPK) [1] [2] [3] [4] . CaMKK2 activity is itself also highly regulated both by phosphorylation and by binding to calcium-calmodulin. Of the multiple phosphorylation sites within CaMKK2 some have been shown in cell lines to be dependent on the activity of cyclin-dependent kinase 5 (CDK5) and glycogen synthase kinase 3 (GSK3) [5] . A number of autophosphorylation sites have also been identified within CaMKK2. Phosphorylation can occur both in mammalian cell lines and during recombinant expression of the kinase in bacteria. The relationship between these regulatory modifications and interactions remains to be fully defined. CaMKK2 is predominantly expressed in the brain and central nervous system and in immune cells [6] [7] [8] .
In the brain and the central nervous system it promotes glycolytic metabolism in the neurons as well as regulating whole-body energy metabolism by functioning downstream of ghrelin in the hypothalamus [9, 10] . In immune cells it has been reported to sustain macrophage proliferation in response to inflammation and immunological insults [8] . CaMKK2 was also recently reported to be overexpressed in prostate cancers under the control of a transcription factor, the androgen receptor, and to enhance glycolysis and anabolic metabolism to support tumour development [11] .
These physiological associations have led to considerable interest over the last decade in the development of CaMKK2 inhibitors and the most specific example to date, called STO-609 (PubChem CID: 3467590), is known to be a selective ATP-competitive CaMKK inhibitor [12, 13] . STO-609 is a naphthoyl fused benzimidazole cell-permeable compound reported to have a low nanomolar IC 50 value as determined by in vitro kinase assays against CaMKKs [12] . However, it also inhibits a number of other kinases including one of its primary M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 substrates, AMPK, at a 1 µM concentration in the same assays and is often used at 10-20 µM when applied to cell-lines [14] . Consequently in order to progress CaMKK2 inhibitors into a clinical setting additional drug development is required. Despite the intense interest in the function of this kinase only two structures have yet been determined; the inhibitor-kinase domain complex [13] and a peptide-derived from the kinase in complex with calmodulin (CaM) [15] . Consequently in order to accelerate the development of new CaMKK2 inhibitors and to obtain further mechanistic understanding of this important kinase, more structural and biophysical data are needed.
Here we report the development of an in vitro assay that assesses the binding properties of STO-609 by exploiting the intrinsic fluorescent properties. We performed this assay using recombinant human full-length CaMKK2, CaMKK2 F 267 G mutant, and CaMKK2 in complex with calmodulin (CaMKK2:CaM), for which we report the complete expression (E. coli) and purification protocol in the attached Date in Brief report, section 2. The novel fluorescent in vitro assay has allowed us to characterise the relationship between STO-609 and CaMKK2, both in the presence and absence of calcium and CaM. Furthermore, we have established that recombinant expressed CaMKK2 constructs were highly phosphorylated and that this had a pronounced effect on the binding measurements performed with STO-609 on CaMKK2.
These findings highlight the importance for careful assessment of the protein composition/quality in kinase drug screenings. Moreover, this assay offers a drug screen for future drug development initiatives that is not kinase activity-dependent, and we would propose using this assay in an STO-609 displacement screen with new candidate inhibitors. This assay would be applicable both for CaMKK2 and other kinases inhibited by STO-609 [1] .
Material and Methods
Unless otherwise specified, all chemicals and reagents were purchased from Sigma-Aldrich at BioUltra reagent grade.
Fluorescence Spectroscopy
All fluorescent data was collected using a FP8500 spectrofluorometer (Jasco, Germany) with monochrometer slit widths set at 5 nm at 24 °C. Mea surements were taken in 1. 
Fluorescent data analysis for determining affinity constant
The volume corrected change in fluorescence (∆ F) after each addition of STO-609 was estimated according to equation 1.
With V 0 as the initial sample volume, ‫ݒ‬ is volume of titrant added in ith increments throughout the experiment. ‫ܨ‬ is the fluorescence signal observed and ‫ܨ‬ ௩ volume adjusted signal measurement were recorded at an excitation wavelength of 400 nm and an emission wavelength of 500 nm.
The obtained values for ‫ܨ‬ ௩ were plotted as a function of the STO-609 concentration. Spectra were corrected by subtraction of background buffer scans, but were not smoothed. We used the data analysis program GraphPad Prism version 6.00 for Mac (GraphPad Software, www.graphpad.com) to analyse the generated data points to obtain a value for the ‫ܭ‬ assuming only a single binding site (N=1).
[CaMKK2] is the final concentration and [STO] the dilution corrected value, similar to the volume correction performed for ‫ܨ‬ . ‫ܨ‬ is average (n=3) fluorescence at the start of the titration, and ‫ܨ‬ the average fluorescence and fluorescence quenching after the final substrate addition.
To analyze the fluorescence binding data we applied a 1 : 1 binding model in accordance with the 1 : 1 molecular stoichiometry of binding between CaMKK2 and STO-609 as observed in the crystal structure [13] .
Dephosphorylation of protein samples
Dephosphorylation of CaMKK2 and CaMKK2:CaM was achieved by incubating the samples with 0.25 µl or 0.5 µl lambda phosphatase (Lambda PP; NEB) according to the manufacturers protocol for two hours at 30 °C prior to measurements.
NanoLC-LTQ Orbitrap Mass Spectrometry
The 2ZV2) [13] . Based on the structure of STO-609 we speculated that it could have intrinsic fluorescent properties and during the course of this study this has been confirmed in a recent publication, reporting background fluorescence that interfered with the imaging experiments [17] . To determine the excitation wavelength of STO-609, we varied the excitation wavelength applied to 600 nM free drug in protein buffer by increments of 5 nm on a range from 200 to 685 nm measuring an emission wavelengths spectrum from 210 to 700 nm. An excitation wavelength of 400 nm was defined as optimal with a maximum emission wavelength at 533 nm (Fig. 1A) .
Having established this for the free drug we then sought to assess how this changed upon addition of purified CaMKK2. By excitation at a wavelength of 400 nm, we measured the effect of titrating recombinant CaMKK2 to 2 µM STO-609 and collected an emission spectrum in the range from 400 to 750 nm. We observed a ~ 30 nm blue-shift with a maximum emission wavelength peak at ~ 500 nm (Fig. 1B) accompanied by a 10-fold enhancement of the quantum yield upon saturation (Fig. 1C) ; two observations that strongly indicate that STO-609 binding to CaMKK2 results in shielding of the drug/chromophore from the aqueous environment, supporting the reported mainly hydrophobic interaction [13] .
Therefore, binding of STO-609 to CaMKK2 can be quantitated by the change of intrinsic fluorescence of STO-609 at binding equilibrium, measuring emission at 500 nm. We went on to generate a saturation curve for this fluorescent shift using 210 nM of purified CaMKK2 to which we added increasing concentrations of STO-609 in a range from 0 to 100 nM. We Thr 518 [5, 18, 19] ) and some of which, particularly those in the activation segment (Ser 334 , Ser 340 , Ser 345 , Thr 347 , Thr 350 ), were novel ( Fig. 2 and Table S1 ). To determine whether the phosphorylation status of the kinase impacted on the saturation of the fluorescence signal we incubated the protein with phosphatase prior to measurements. Via mass spectrometry we could determine de-phosphorylation ratios of 0.6 up to 1.0 for the single phosphorylation sites Ser 345 and Thr 347 , which showed prior phosphatase treatment the highest phosphorylation rates. Comparing STO-609 binding affinities for CaMKK2 and CaMKK2:CaM before and after phosphatase treatment, assessed by fluorometric emission as described above, we could see a clear shift of saturation before and after incubation with phosphatase.
Phosphatase treatment resulted in saturation of the fluorescence signal for both CaMKK2 and CaMKK2:CaM at higher STO-609 concentrations. Interestingly the impact of phosphatase treatment was to increase the K D for CaMKK2 from ~17 nM to ~49 nM whereas the K D for CaMKK2:CaM was reduced from ~17 nM to ~7 nM. This differential response may imply that there are differential effects of phosphorylation on the STO-609 binding pocket according to whether CaM is also bound to CaMKK2 or not. This merits further molecular dissection in future studies.
Additional impacts on the saturation properties of the assay may arise from protein misfolding or changes in the solubility properties upon the binding of STO-609 independent of the phosphorylation status -these are generic challenges in working with recombinant proteins.
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CaMKK2 has been reported to be regulated by both CaM-binding and by phosphorylation. To assess the impact of CaM interaction on the binding to STO-609 we also co-purified CaMbound CaMKK2 (CaMKK2:CaM) (see DIB report). We applied a 1 : 1 binding model in accordance with the 1 : 1 molecular stoichiometry of binding observed in the crystal structure of STO-609 bound to the kinase domain of CaMKK2 [13] . In this comparison we observed an identical K D of STO-609 binding, 17 ± 6 nM and 17 ± 7 nM with and without CaM, respectively, also reflected in overlapping binding curves with and without CaM (Table 1 and   Fig. 2C) . This also confirmed the robustness and reproducibility of our assay. CaMKK2 is also expressed as a number of isoforms which each have their own regulatory characteristics -differing in their phosphorylation profiles and responses to CaM binding [3, 20] . In this study we have expressed and purified isoform 3 which, whilst binding to calmodulin, does not
show changes in its kinase activity in response to this interaction [3] . The unchanged K D we have observed here with or without calmodulin corroborates this observation but given these isoform studies future work should extend the assay to the full range of isoforms. This is the first example of a binding study that utilises the intrinsic fluorescent properties of STO-609 to assess and describe the binding properties with its target kinase in a pure in vitro system.
To further verify that the blue-shift in fluorescent upon incubating STO-609 with CaMKK2 was due to its association with the ATP-binding pocket, we titrated STO-609 to 200 nM CaMKK2 up to approximately 50 % saturation (~60 nm STO-609) before titrating highly concentrated ATP into the sample (Fig. 3A) .This experiment allowed us to show the loss of binding between STO-609 and CaMKK2, indicated by a decreasing fluorescent signal at 500 nm, implying its replacement by ATP. However, an ATP / STO-609 ratio of approximately 5000 was needed to lower the signal to 50 % which demonstrates the strong binding affinity between the drug and the kinase. As a control, we added GTP in similar A recent structural study in which STO-609 was soaked into crystals of the kinase domain of CaMKK2 indicated that a number of amino acids in the ATP binding pocket were important for the association [13] . Our fluorescence assay provides the opportunity to further assess the importance of these amino acids for the drug interaction. As a proof-of-principle we mutated Phe 267 , a so-called 'gatekeeper' residue in the ATP-binding pocket, to glycine. This amino acid was selected based on sequence alignments with other kinases that have previously been mutated at 'gatekeeper' residues to support chemical genetic screens for novel kinase substrates in combination with bulky nucleotide analogues [21, 22] (Fig. 3B) .
This mutation abolished the STO-609 binding to the recombinant kinase in our fluorescent assay which therefore provides a tool for evaluating critical residues directly in an in vitro system (Fig. 3C) . 
Highlights
• STO-609 is intrinsically fluorescent and is used to assess binding by CAMKK2
• Phenylalanine-267 is critical for the interaction with STO-609
• Recombinant CAMKK2 is phosphorylated and we find novel activation segment sites
• Binding of STO-609 by recombinant CaMKK2 is phosphorylation-dependent
• The assay provides a tool to support future drug screening and functional studies
